Plasma Cell Leukemia Occurring in a Patient with Thrombocythemia Treated with Hydroxyurea and Busulphan

REFERENCES

• Kyle, R.A., Maldonado, J.E. and Bayrd, E.D. (1974) "Plasma cell leukemia. Report on 17 cases", Arch. Intern. Med., 133, 813–818.
   Web of Science ®Google Scholar
• Kosmo, MA. and Gale, R.P. (1987) "Plasma cell leukemia", Semin. Hematol., 24, 202–208.
   Web of Science ®Google Scholar
• Bernasconi, C., Castelli, G., Pagnucco, G. and Brusamolino, E. (1989) "Plasma cell leukemia: a report on 15 patients", Eur. J. Haematol., 51(suppl), 76–83.
   Google Scholar
• Garcia Sanz, R., Orafao, A., Gonzales, M., Tabernero, M., Blade', J., Moro, Mi., et al. (1999) "Primary Plasma Cell Leukemia: Clinical, Immunophenotyping, DNA Ploidy, and Cytogenetic Characteristics", Blood 93(3), 1032–1037.
   PubMed Web of Science ®Google Scholar
• Pasqualetti, P., Festuccia, V., Collacciani, A., Acitelli, P. and Casale, R. (1996) "Plasma cell leukemia. A report of patients and review of the literature", Panminerva Med., 38(3), 179–184.
   PubMed Web of Science ®Google Scholar
• Hayman, S.R. and Fonseca, R. (2001) "Plasma cell leukemia", Curr. Treat. Options °ilea, 2(3), 205–216.
   PubMedGoogle Scholar
• Prosper, F., Borbolla, J.R., Rifon, J., Cuesta, B., Fernandez, J., Pinacho, A., et al. (1992) "Coexistence of Essential Thrombocythe-mia and Multiple Myeloma", Ann. Hematol., 65(2), 103–105.
   Web of Science ®Google Scholar
• Kelsey, P.R. and Patel, K. (1995) "Essential Thrombocythaemia followed by multiple myeloma in the same patient", Clin. Lab. Haematol., 17(4), 349–351.
   PubMedGoogle Scholar
• Costello, R., Sainty, D., Bouabdallah, J.P., Fernand, J.P., Delmer, A., Divine, M., et al. (2001) "Primary plasma cell leukaemia: a report of 18 cases", Leuk. Res., 25(2), 103–107.
   Google Scholar
• Mak, Y.K., Chan, C.H., Chen, Y.T., Lau, S.M., So, C.C. and Wong, K.F. (2003) "Consolidation therapy with autologus blood stem cell transplantation in a patient with primary plasma cell leukaemia", Clin. Lab. Haem., 25, 55–58.
   PubMedGoogle Scholar
• Vela-Ojeda, J., Garcia-Ruiz Esparanza, M.A., Rosas-Cabral, A., et al. (2002) "Intermediate doses of melphalan and dexamethasone are better than vincristine, adriamycin, and dexamethasone (VAD) and polychemotherapy for the treatment of primary plasma cell leukaemia", Ann. Hematol., 81(7), 362— 367.
   Web of Science ®Google Scholar
• Christou, L., Hatzimichael, E., Chaidos, A., Tsiara, S. and Bourantas, K.L. (2001) "Treatment of plasma cell leukemia with vincristine, liposomal doxorubicin and dexamethasone", Eur. J. Haematol., 67, 51–53.
   PubMed Web of Science ®Google Scholar
• Panizo, C., Rifon, J., Rodriguez-Wilhelmi, P., Cuesta, B. and Rocha, E. (1999) "Long-term survival in primary plasma cell leukemia after therapy with VAD, autologus blood stem cell transplantation and interferon-alpha", Acta. Haematol., 101(4), 193— 196.
   Google Scholar
• Sica, S., Chiusolo, P., Salutari, P., Piccirillo, N., Laurenti, L., Ortu La Barbera, E., et al. (1998) "Long-lasting complete remission in plasma cell leukemia after aggressive chemotherapy and CD34-selected autologus peripheral blood progenitor cell transplant: molecular follow-up of minimal residual disease", Bone Marrow Transplant, 22(8), 823–825.
   PubMed Web of Science ®Google Scholar
• Hovenga, S., Wolf de J, TM., Klip, H., et al. (1997) "Consolidation therapy with autologus stem cell transplantation in plasma cell leukaemia after VAD, high-dose cyclophosphamide and EDAP courses: a report of three cases and a review of the literature", Bone Marrow Transplant, 20, 901–904.
   Google Scholar
• Schwarzenbach, H. (2002) "Expression of MDR1/P-glycoprotein, the multidrug resistance protein MRP, and the lung-resistance protein LRP in multiple myeloma", Med. Oncol., 19(2), 87–104.
   Google Scholar
• Raaijmakers, H.G.P., Izquierdo, M.A.I., Lokhorts, H.M., Dee Leeuw, C., et al. (1998) "Lung-Resistance-Related Protein Expres-sion is a negative predictive factor for response to conventional low but not to intensified dose alkylating chemotherapy in Multiple Myeloma", Blood, 9, 1029–1036.
   Google Scholar
• Fishman, M.N. and Sullivan, D.M. (2001) "Application of Resistance Reversal Agent in Hematologic Malignances", Current Clinical Practice Hematol., 5, 343–358.
   Google Scholar
• Mohrbacher, A.F., Gregory, S.A., Gabriel, D.A., Rusk, J.M. and Giles, F.J. (2002) "Liposomal daunorubicin (DaunoXome) plus dexamethasone for patients with multiple myeloma. A phase II International Oncology Study Group study", Cancer, 15, 2645 — 2652.
   Google Scholar
• Liozon, E., Brigaudeau, C., Trimoreau, F., Desangles, F., Fermeaux, V., Praloran, V., et al. (1997) "Is treatment with hydroxyurea leukemogenic in patients with essential thrombocythe-mia? An analysis of three new cases of leukaemic transformation and review of the literature", Hematol. Cell. Ther., 39(1), 11–18.
   PubMedGoogle Scholar
• Finazzi, G., Ruggieri, M., Rodeghiero, F. and Barbui, T. (2000) "Second malignancies in patients with essential thrombocythaemia treated with busulphan and hydroxyurea; long-term follow-up of a randomized clinical trial", Br. J. Haematol., 110, 577–583.
   Web of Science ®Google Scholar
• Murphy, S., Peterson, I., Iland, H. and Laszlo, J. (1997) "Experience of the Polycythemia Vera Study Group with Essential Thrombocythaemia: a final report on diagnostic criteria, survival and leukemic transition by treatment", Seminars in Hematology, 34, 29–39.
   Google Scholar
• Randi, ML., Fabris, F. and Girolami, A. (2000) "Leukemia and myelodysplasia effect of multiple cytotoxic therapy in Essential Thrombocythemia", Leuk. Lymphoma, 37, 379— 385.
   PubMed Web of Science ®Google Scholar
• Raspadori, D., Damiani, D., Michieli, M.G., et al. (2002) "CD56 and PGP expression in acute myeloid leukemia: impact on clinical outcome", Haematologica, 87, 1135 —1140.
   PubMed Web of Science ®Google Scholar